11C-Pittsburgh B PET imaging in cardiac amyloidosis

JACC: Cardiovascular Imaging

Volumn 8, Issue 1, 2015, Pages 50-59

  Lee, Seung Pyo ^a,b   Lee, Eun Seong ^a   Choi, Hongyoon ^a   Im, Hyung Jun ^a   Koh, Youngil ^b   Lee, Min Ho ^a,b   Kwon, Ji Hyun ^b   Paeng, Jin Chul ^a   Kim, Hyung Kwan ^a,b   Cheon, Gi Jeong ^a   Kim, Yong Jin ^a,b   Kim, Inho ^b   Yoon, Sung Soo ^b   Seo, Jeong Wook ^a   Sohn, Dae Won ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Cardiac amyloidosis; Cardiac magnetic resonance; Echocardiography; Pittsburgh B compound; Positron emission tomography

Indexed keywords

PITTSBURGH COMPOUND B; BENZOTHIAZOLE DERIVATIVE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGED; CARDIOVASCULAR MAGNETIC RESONANCE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART MUSCLE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; MALE; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; PATIENT HISTORY OF CHEMOTHERAPY; PET-CT SCANNER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; AMYLOIDOSIS; CARDIOMYOPATHIES; DIAGNOSTIC USE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BENZOTHIAZOLES; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84922559659     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2014.09.018     Document Type: Article

References (22)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337: 898-909.
3. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91: 141-57.
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
5. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
6. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
7. Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010;1804:1405-12.
8. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20.
9. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img 2010;3:155-64.
10. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47.
11. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
12. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (18)Fflorbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.
13. Glaudemans AW, Slart RH, Zeebregts CJ, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.
14. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
15. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461-74.
16. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804.
17. Bacskai BJ, Hickey GA, Skoch J, et al. Fourdimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003;100:12462-7.
18. Burack MA, Hartlein J, Flores HP, Taylor- Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.
19. Dore V, Villemagne VL, Bourgeat P, et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 2013;70:903-11.
20. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9-13.
21. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol Img 2009;2:1369-77.
22. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.